Engineering & Optimization Priorities for Proposed New US Biopharma Plants

i 3 Table Of Content

The US is on the precipice of a major biopharmaceutical manufacturing boom. In an effort to safeguard against potential tariffs and supply chain disruptions, many of the world’s leading biopharma companies have announced initiatives to construct new US production sites in the coming years. According to Manufacturing Today, fifteen biopharmaceutical companies plan to collectively invest more than $270 billion into US-based manufacturing and research infrastructure over the next ten years.

After biopharma organizations finalize their plans for their proposed production sites, they’ll soon begin designing the layout of each plant. In the early stages of biopharma plant design, planners are faced with decisions that can either improve or complicate the day-to-day operations of the real, functioning facility. While sites can still be improved to accommodate production conditions after completion, plants that are optimally designed can produce more value from the start.

When designing a new biopharma plant, there are several factors planners should evaluate that can help streamline operations, maximize capacity, and build in flexibility for future production changes. We’ll break down some of the biggest engineering and optimization priorities to consider in a few key areas of new production plants.

Capacity

The capacity of the proposed production site will have perhaps the biggest impact on the plant’s supply chain and overall profitability. If the plant is not designed to allow production output to match demand today and in future market increases, the organization will lose potential revenue and have operations underperforming on efficiency.

In the early design stages, consider how different decisions will affect overall production capacity. If a design adds bottlenecks to a process or contains unproductive use of space, how much capacity will be sacrificed and how much value will be lost? Could a different plant design open more room to add production lines now or in the future? Many manufacturing plants eventually produce different product mixes as market needs change, so creating room in the site for flexibility to increase capacity or adapt processes is key to maintaining a higher production capacity.

Inventory

The amount of inventory space required for a new biopharma site can vary based on several factors, including the specific products being manufactured and the production capacity of the plant. If the plant design doesn’t include sufficient space for inventory, the site won’t have enough supplies on hand to reach capacity; if there’s excess inventory, it will take unnecessary square footage from valuable additional production space. It’s also important to consider the design of media and buffer storage required to support mainline production.

When allotting inventory space in a plant design, it can be helpful to test the tradeoffs between additional material storage and alternative uses for the additional square footage to determine the best use of the space. Planners should also consider their organization’s projected demand forecasts and inventory philosophy, such as Just-In-Time or safety stock, to make the best decisions about plant storage.

Equipment Utilization & Downtime

The production layout created when designing the plant will have a major impact on the site’s productivity. An inefficient design can slow down the production process, resulting in regular downtime and decreased equipment utilization. This is especially common for plants that will produce several different biopharma products and require changeovers or extra cleaning between product runs. Downtime will lower the site’s productivity, decrease overall output, and increase waste.

To avoid unnecessary downtime and increase equipment utilization, planners should prioritize designing around production processes that can flow efficiently. They must also watch out for designs that create process bottlenecks, which will further slow down the plant’s productivity and reduce capacity. For plant designs that need to account for product changeovers, planners should consider testing different layouts that will allow for some processes to continue while other equipment is changed over or cleaned to minimize the facility’s total downtime.

Balancing Costs vs. Value Added

One of the biggest tasks plant designers face is creating the most potential value possible with the capital allotted for the new plant’s construction. New US biopharma plants are multi-billion-dollar projects, and executives expect to receive timely returns on their production investments. Planners are encouraged to use every dollar thoughtfully and ensure the expenditure is designed with optimal financial impact.

For each plant design decision, planners should consider if the associated cost is justified by the value it will add to the facility. Often, they are faced with a choice between two potential options and must determine which will be the better choice for the site. They should also consider if there are ways to reduce the required capital for the project with impacting the overall output. If a plant feature or investment isn’t projected to earn a sufficient return, the capital can be reallocated into other enhancements to boost the plant’s value.

VirtECS

Evaluating different plant designs and determining which will create the most value can be very difficult and time-consuming for planners to achieve manually, but getting the right answer will have a big impact on the bottom line. A virtual plant modeling tool like VirtECS can help planners more easily conceptualize and test different plant models to measure the impact of each design decision.

The VirtECS virtual model can be used to quickly model and evaluate a plant design. Once a base case design is established, VirtECS users can propose and test endless what-if scenarios, including debottlenecking improvements, storage right-sizing, buffer/media making strategies, and changes to the product mix. VirtECS can then create a detailed production schedule, which ensures potential bottleneck areas and changeovers are accounted for. VirtECS users can then evaluate the plant design’s ROI based on the schedule’s product throughput to give plant leadership more confidence in the use of capital expenditure. To learn more about the full benefits a VirtECS virtual model can provide biopharma organizations during new plant construction, you can download our short guide.

News & Insight

3 Common Myths About Factory Digital Twins

Biopharma companies setting their plans for 2027 are overwhelmingly prioritizing digital tools that can provide operational efficiency and...

The Challenges of Continuous Manufacturing for Biopharma Plants: Using Digital Twins and AI to Increase Visibility

Over the last five years, the biopharma industry has seen an increasing rate of adoption for continuous manufacturing processes. According...

Winning the Biopharma Future with an Adaptable Factory Digital Twin

Biologics products represent one of the fastest-growing sectors in the pharmaceutical industry. As biologics therapies become more...

Ready To Learn More?

Request a Discovery Call

VirtECS® software, created by Advanced Process Combinatorics, Inc. (APCI), delivers a range of capabilities built around proprietary core solver technology. This call will allow our team to gain an initial understanding of your organization’s needs and how VirtECS® can deliver results.

Complete the form and a member of our team will contact you to coordinate the most convenient option for your schedule.

 

  • This field is for validation purposes and should be left unchanged.